The Emergence of the Potential Therapeutic Targets: Ultrasound-Based Radiomics in the Prediction of Human Epidermal Growth Factor Receptor 2-Low Breast Cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ultrasound radiomics can predict HER2-low breast cancer expression. This radiomics score (RS) effectively differentiates HER2-zero from HER2-low and HER2-positive cases in multiple datasets.
Area Of Science
- Radiology
- Oncology
- Medical Imaging
Background
- HER2 expression is crucial for breast cancer (BC) treatment decisions.
- Accurate prediction of HER2 expression, particularly HER2-low, is vital for personalized therapy.
- Conventional imaging methods have limitations in predicting HER2 status.
Purpose Of The Study
- To evaluate the efficacy of ultrasound (US)-based radiomics features in predicting HER2-low expression in breast cancer patients.
- To develop and validate a radiomics score (RS) for HER2 expression prediction using conventional US images.
Main Methods
- A multicenter study included 383 patients (training), 233 (validation), and 149 (external validation).
- Radiomics features were extracted from conventional US images.
- Minimum redundancy maximum relevancy and least absolute shrinkage and selector operation algorithms were used to generate an US-based radiomics score (RS).
- Multivariable logistic regression and receiver operating characteristic curve analysis (AUC) were employed to assess diagnostic performance.
Main Results
- The RS demonstrated strong performance in predicting HER2-low expression across all datasets.
- AUC values for differentiating HER2-zero from HER2-low/positive cases were 0.81 (training), 0.84 (validation), and 0.82 (external validation).
- The RS showed good performance in subgroup analyses, distinguishing HER2-zero from HER2 1+, 2+, and HER2-low tumors (AUC range: 0.79-0.87).
Conclusions
- The US-based radiomics score (RS) is an effective tool for predicting HER2-low expression in breast cancer.
- This non-invasive imaging-based approach can aid in treatment selection for breast cancer patients.
- Radiomics offers a promising avenue for improving the prediction of HER2 status in breast cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
